Light speed ultra 16 slice

HSRS was performed using the Radiosurgery System (Accuray, Sunnyvale, CA, USA). Patients were immobilized with a custom thermoplastic mask and underwent both computed tomography (CT, GE Light speed Ultra 16 Slice, USA) examinations with a slice thickness of 1.25 mm and MRI with a slice thickness of 2 mm acquired from both T1 postcontrast and T2 flair images. CT and MRI scans were then fused using the planning system for contouring.
Radiation oncologists, neurosurgeons, and radiation physicists participated in tumour delineation, planning, and dose selection. Gross tumour volume (GTV) was defined as the gadolinium-enhanced tumour on the T1-weighted series. The clinical tumour volume (CTV) was considered equal to the GTV. The planning target volume (PTV) was a uniform 2 mm expansion of the CTV, and FLAIR abnormalities were not included in the treatment volume. Multiplan (Accuray, Sunnyvale, CA, USA) software was used for inverse planning. The prescribed dose to PTV was determined according to the target volume, site, previous irradiation volume and total dose, and the interval between treatments.
The use of systemic therapy after HSRS was decided by the treating physicians. Thus, the regimens were individualized, and most commonly, bevacizumab, temozolomide or clinical trials were recommended.

Patients were immobilised with a custom thermoplastic mask and underwent localised 1.25-mm thin-slice computed tomography (CT, GE Light speed Ultra 16 Slice, San Francisco, CA, USA) and 2-mm thin-slice magnetic resonance imaging (MRI) including T1 post-contrast and T2 FLAIR images. CT and MRI scans were then fused using the planning system for contouring. HSRT was delivered by a CyberKnife Radiosurgery System (Accuray, Sunnyvale, CA, USA).
Radiation oncologists, neurosurgeons, and radiation physicists participated in tumour delineation and planning. The prescribed dose was 25.0 Gy in 5 fractions. The gross tumour volume (GTV) was defined as the gadolinium-enhanced tumour on the T1-weighted series. The clinical tumour volume (CTV) was considered equal to the GTV. The planning target volume (PTV) was a uniform 1-mm expansion of the CTV. Multiplan software was used for inverse planning. The prescribed isodose line to the PTV was determined according to the target volume, site, previous irradiation volume, and interval between treatments. Anlotinib (Tai-Tianqing Pharmaceutical Co., Ltd., Jiangsu, China) was prescribed at a dose of 12 mg daily for 14 consecutive days every 3 weeks from the first day of HSRT.